
Pharmaceutical Compliance and Enforcement Answer Book (Eleventh Edition) provides readers with a solid framework for understanding and navigating the rigorous—and regularly overlapping—requirements imposed by varying governmental authorities and private parties upon the pharmaceutical industry. This treatise analyzes the basic foundations of pharmaceutical industry regulation through the lens of current legal, regulatory, and compliance developments.
Highlights of the recent update include:
- A new chapter 13, Radical Transparency and Product Liability Exposure—The New Frontier, examining the FDA’s new policy of releasing all Complete Response Letters as they’re issued to drug sponsors, as well as the implications of this policy on product liability claims.
- Updated guidance in Chapter 2, FDA Enforcement—Facility Inspections on best practices for handling FDA inspections, including a sample corporate policy to ensure compliance with recordkeeping and documentation requirements.
- Amendments to Chapter 5, Federal and State Regulation and Enforcement of Pharmaceutical Manufacturers’ Advertising and Promotional Activity, reflecting the latest rules, guidance, and enforcement actions regarding pharmaceutical manufacturer advertising and promotional activity.
- Revisions to include the current enforcement environment related to off-label promotion (Chapter 6), including further discussion of the FDA’s final guidance on scientific information on unapproved uses of off-label promotion in relation to approved/cleared medical products (Chapter 7).
- Inclusion of a circuit split regarding interpretation of language in the Patent Protection and Affordable Care Act which may significantly impact False Claims Act damages in AKS-based cases (Chapter 14).
Order a print copy today.








